Citigroup Maintains Buy on Cabaletta Bio, Lowers Price Target to $8

Benzinga · 1d ago
Citigroup analyst Samantha Semenkow maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and lowers the price target from $10 to $8.